TB-500
TB-500 is marketed for recovery and tissue regeneration, but it remains outside routine lawful compounding pathways.
Current status
Restricted
Tissue regeneration, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Frequently discussed alongside BPC-157 in reform conversations, though current federal status remains restrictive.
Primary Use
Tissue regeneration
Regulatory Timeline
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Sep 29, 2023
Current status signal recorded: Included among peptides treated as difficult to justify for compounding..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Get notified...
Get notified when TB-500 status changes
State-specific notes
California
Wellness clinics rarely obtain it from compliant pharmacies.
New York
Sourcing tends to disappear quickly after enforcement shifts.